Literature DB >> 33941603

Quetiapine for primary insomnia: Consider the risks.

Vania Modesto-Lowe1, Agata K Harabasz2, Sophia A Walker3.   

Abstract

The second-generation antipsychotic drug quetiapine (Seroquel) is increasingly being used off-label for treating insomnia in the general population, possibly to avoid standard medications with known addictive qualities and adverse side effects. However, evidence to support using it in this way is scant, and quetiapine is associated with weight gain and other metabolic effects. It must be used cautiously and with appropriate monitoring for adverse effects and abuse.
Copyright © 2021 The Cleveland Clinic Foundation. All Rights Reserved.

Entities:  

Year:  2021        PMID: 33941603     DOI: 10.3949/ccjm.88a.20031

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN: 0891-1150            Impact factor:   2.321


  3 in total

Review 1.  Adding Insult to Injury: Sleep Deficiency in Hospitalized Patients.

Authors:  Wissam Mansour; Melissa Knauert
Journal:  Clin Chest Med       Date:  2022-06       Impact factor: 4.967

2.  Use of low-dose quetiapine increases the risk of major adverse cardiovascular events: results from a nationwide active comparator-controlled cohort study.

Authors:  Mikkel Højlund; Kjeld Andersen; Martin T Ernst; Christoph U Correll; Jesper Hallas
Journal:  World Psychiatry       Date:  2022-10       Impact factor: 79.683

3.  Characteristics and predictors of off-label use of antipsychotics in general population sample.

Authors:  Eero Pirhonen; Marianne Haapea; Nina Rautio; Tanja Nordström; Miia Turpeinen; Outi Laatikainen; Hannu Koponen; Jenni Silvan; Jouko Miettunen; Erika Jääskeläinen
Journal:  Acta Psychiatr Scand       Date:  2022-07-12       Impact factor: 7.734

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.